ArticleMicrobial cell factories2017
Improving Escherichia coli membrane integrity and fatty acid production by expression tuning of FadL and OmpF.
Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 71 citations in OpenAlex.
- Mechanism of Synergistic Action of Isochlorogenic Acid C and Ciprofloxacin Against Drug-ResistantBiomolecules · 2026Article
- Genetic Regulation and Breeding Application of Medium-Chain Fatty Acids Metabolism in Rice.Biology · 2025Review
- TamL is a Key Player of the Outer Membrane Homeostasis in Bacteroidota.Journal of molecular biology · 2025Article
- Identification and Characterization of Two Novel Members of the FamilyMicroorganisms · 2025Article
- Genome-scale CRISPRi screen identifies pcnB repression conferring improved physiology for overproduction of free fatty acids in Escherichia coli.Nature communications · 2025Article
- A novel FadL family outer membrane transporter is involved in the uptake of polycyclic aromatic hydrocarbons.Applied and environmental microbiology · 2025Article
- Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids.International journal of pharmaceutics: X · 2024Review
- Assimilation of phthalate esters in bacteria.Applied microbiology and biotechnology · 2024Review
- Identification of crucial roles of transcription factor IhfA on high production of free fatty acids inSynthetic and systems biotechnology · 2024Article
- Pseudomonas putida as a platform for medium-chain length α,ω-diol production: Opportunities and challenges.Microbial biotechnology · 2024Article
- Overcoming barriers to medium-chain fatty alcohol production.Current opinion in biotechnology · 2024Review
- Integration of (S)-2,3-oxidosqualene enables E. coli to become Iron Man E. coli with improved overall tolerance.Biotechnology for biofuels and bioproducts · 2023Article
- Efficient biosynthesis of (R)-mandelic acid from styrene oxide by an adaptive evolutionary Gluconobacter oxydans STA.Biotechnology for biofuels and bioproducts · 2023Article
- Mediator Engineering ofApplied and environmental microbiology · 2022Article
- Control of Unsaturation inBiochemistry · 2022Article
- Overview of the Cellular Stress Responses Involved in Fatty Acid Overproduction in E. coli.Molecular biotechnology · 2022Review
- Insights into the Degradation of Medium-Chain-Length Dicarboxylic Acids in Cupriavidus necator H16 Reveal β-Oxidation Differences between Dicarboxylic Acids and Fatty Acids.Applied and environmental microbiology · 2022Article
- Characterizing Escherichia coli's transcriptional response to different styrene exposure modes reveals novel toxicity and tolerance insights.Journal of industrial microbiology & biotechnology · 2021Article
- Elucidation of transient protein-protein interactions within carrier protein-dependent biosynthesis.Communications biology · 2021Article
- Enhancement of Sphingolipid Synthesis Improves Osmotic Tolerance of Saccharomyces cerevisiae.Applied and environmental microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConstruction of microbial biocatalysts for the production of biorenewables at economically viable yields and titers is frequently hampered by product toxicity. Membrane damage is often deemed as the principal mechanism of this toxicity, particularly in regards to decreased membrane integrity. Previous studies have attempted to engineer the membrane with the goal of increasing membrane integrity. However, most of these works focused on engineering of phospholipids and efforts to identify membrane proteins that can be targeted to improve fatty acid production have been unsuccessful.
resultsHere we show that deletion of outer membrane protein ompF significantly increased membrane integrity, fatty acid tolerance and fatty acid production, possibly due to prevention of re-entry of short chain fatty acids. In contrast, deletion of fadL resulted in significantly decreased membrane integrity and fatty acid production. Consistently, increased expression of fadL remarkably increased membrane integrity and fatty acid tolerance while also increasing the final fatty acid titer. This 34% increase in the final fatty acid titer was possibly due to increased membrane lipid biosynthesis. Tuning of fadL expression showed that there is a positive relationship between fadL abundance and fatty acid production. Combinatorial deletion of ompF and increased expression of fadL were found to have an additive role in increasing membrane integrity, and was associated with a 53% increase the fatty acid titer, to 2.3 g/L.
conclusionsThese results emphasize the importance of membrane proteins for maintaining membrane integrity and production of biorenewables, such as fatty acids, which expands the targets for membrane engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.